Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.36 |
| ▸ | FNTB | P49356 | 3/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018262 | 0.91 | CXCR4 (0.57) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6018574 | 0.90 | CXCR4 (0.51) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6682711 | 0.90 | CXCR4 (0.40) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL7024762 | 0.90 | CXCR4 (0.47) | CXCR4FOLH1DHFRMAPK14KMT2A | |
| SCHEMBL6690684 | 0.89 | CXCR4 (0.40) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6690468 | 0.89 | CXCR4 (0.40) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6019671 | 0.89 | CXCR4 (0.49) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6018567 | 0.87 | CXCR4 (0.54) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6018843 | 0.87 | CXCR4 (0.51) | CXCR4FOLH1CASRFNTAFNTB | |
| SCHEMBL6018749 | 0.86 | CXCR4 (0.51) | CXCR4FOLH1CASRFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | KUREHA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1389460-A1 | CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND | Kureha Chemical Industry Co., Ltd. (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | CXCR4 2185/4885FOLH1 1290/4885CASR 4571/4885 |
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | CXCR4, CXCR1, CXCR2 | CXCR4 1/4885FOLH1 2694/4885CASR 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.